G
Genetic Archaeology
GENETIC ARCHAEOLOGY // PROFILE

UGT1A1

UDP Glucuronosyltransferase Family 1 Member A1

CHR 2
2q37.1

Overview

The UGT1A1 gene handles the body’s primary cleanup route for bilirubin, the yellow pigment produced when red blood cells recycle normally. In Phase II liver metabolism, UGT1A1 attaches glucuronic acid so bilirubin dissolves smoothly into bile.

In ~10% of adults, reduced transcription from the common *28 variant produces Gilbert’s syndrome—mild, harmless rises in unconjugated bilirubin alongside crucial dosing implications for oncology agents such as irinotecan.

📍 Position
2q37.1 (Chromosome 2)
🏷️ Category
Detoxification & Bilirubin
🧪 Function
Phase II Glucuronidation Enzyme
📊 Influence
Bilirubin clearance & PGx

Function of UGT1A1

UGT1A1 serves dual duty: clearing endogenous bilirubin and steroid hormones while conjugating active drug metabolites such as SN-38 (the potent cytotoxic metabolite of irinotecan).

Key Aspects:

🟡 Benign Gilbert’s Syndrome (*28/*28)

With ~30% enzyme capacity, fasting, illness, intense workouts, or sleep debt briefly bump indirect bilirubin slightly—clinically harmless and even epidemiologically linked with antioxidant benefits.

💊 Irinotecan & Atazanavir Safety

In oncology, reduced SN-38 clearance in *28/*28 or *6/*6 patients elevates severe neutropenia and diarrhea risk unless starting irinotecan doses are lowered.

💡 Paradoxical Upside of Mild Bilirubin: Cohort research links mild benign bilirubin elevation in Gilbert’s syndrome to antioxidant vascular protection and lower cardiovascular event rates.

🧬 Genetic Variants (SNPs)

Promoter repeat and coding variants alter UGT1A1 glucuronidation throughput across populations:

rs8175347
2:233760233
Normal (*1)

TA6
/
Reduced (*28)

TA7
UGT1A1*28 Promoter Repeat
Seven TA repeats instead of six weaken promoter activity (~70% drop), explaining most European Gilbert’s cases and CPIC irinotecan warnings.
*28 allele frequency:
~30-35% (Europe)
rs4148323
2:233760498
Normal (*1)

G
/
Reduced (*6)

A
UGT1A1*6 (Gly71Arg)
Decreases enzymatic glucuronidation efficiency by ~50-70% in homozygotes; clinically critical across East Asian ancestry.
*6 allele frequency:
~15-20% (East Asia), <2% (Europe)

Practical Significance

✅ Strategies & Guidance

  • Pre-Chemotherapy Screening: Ensure UGT1A1 genotyping is reviewed before initiating high-dose irinotecan or sacituzumab govitecan.
  • Avoid Prolonged Fasting: Regular balanced meals prevent needless unconjugated bilirubin spikes or mild scleral yellowing.
  • Reassuring Lab Differentiation: Elevated isolated indirect bilirubin with completely normal ALT/AST/GGT and ultrasound confirms benign physiology.

⚠️ Clinical Notes & Risks

  • Oncology Drug Toxicity: Standard irinotecan dosing in *28/*28 carries FDA/CPIC warnings for grade 3–4 neutropenia.
  • Cosmetic Jaundice on HIV Therapy: Protease inhibitor atazanavir blocks UGT1A1 competitively, causing reversible benign yellowing.
  • Rule Out Hemolysis First: Persistent jaundice always merits standard CBC/reticulocyte check initially.
🩺 Medical Disclaimer: Genetic test results for UGT1A1 (UDP Glucuronosyltransferase Family 1 Member A1) should always be interpreted alongside laboratory biomarkers, medications, and qualified medical or genetic counseling.

📚 Data Sources

  • OMIM: #191740 (UDP-Glycosyltransferase 1 Family, Polypeptide A1)
  • dbSNP: rs8175347 (*28), rs4148323 (*6)
  • CPIC Guideline: UGT1A1 Genotype and Irinotecan / Atazanavir Therapy
  • PharmGKB: Clinical Annotations Level 1A for UGT1A1

Last Update: November 2026

Related Genes in Detoxification